lorazepam has been researched along with celecoxib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arolt, V; Cerovecki, A; Dehning, S; Douhe, A; Goldstein-Müller, B; Hetzel, G; Kleindienst, N; Maino, K; Möller, HJ; Müller, N; Riedel, M; Schwarz, MJ; Spellmann, I | 1 |
1 review(s) available for lorazepam and celecoxib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lorazepam and celecoxib
Article | Year |
---|---|
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Dinoprostone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-6; Lorazepam; Male; Middle Aged; Morpholines; Patient Dropouts; Pilot Projects; Psychological Tests; Pyrazoles; Reboxetine; Serotonin; Severity of Illness Index; Sulfonamides | 2006 |